Cabaletta Bio Shares Rose 15% After FDA Approves IND Application for CABA-201
May 16 2023 - 1:42PM
Dow Jones News
By Chris Wack
Cabaletta Bio shares were up 15% to $13.16 on Tuesday after the
company said its second Investigational New Drug application for
CABA-201 has been cleared by the U.S. Food and Drug Administration
for a Phase 1/2 study in patients with active idiopathic
inflammatory myopathy.
The stock hit its 52-week high of $13.34 on May 3, and is up
623% in the past 12 months.
The company said it plans to begin a Phase 1/2 clinical trial of
CABA-201 for the treatment of six patients with dermatomyositis,
six patients with anti-synthetase syndrome, and six patients with
immune-mediated necrotizing myopathy, all in separate parallel
cohorts.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 16, 2023 13:27 ET (17:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jul 2023 to Jul 2024
